SCHEMBL5540343

SCHEMBL5540343

CC(O)(COC(=O)N1CCN(Cc2ccc(Cl)cc2)CC1)Cn1cc([N+](=O)[O-])nc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MGLL Q99685 2/20 0.42
PLA2G7 Q13093 1/20 0.42
ABHD6 Q9BV23 1/20 0.42
VEGFA P15692 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 3/20 0.39
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540333 1.00 DRD2 (0.46) DRD2DRD4SMN1; SMN2ALDH1A1KDM4E
SCHEMBL5546384 0.92 MDH1 (0.42) DRD2DRD4ALDH1A1KDM4EMGLL
SCHEMBL5546388 0.92 MDH1 (0.42) DRD2DRD4ALDH1A1KDM4EMGLL
SCHEMBL5539665 0.90 LSS (0.42) SMN1; SMN2ALDH1A1KDM4EMGLLLMNA
SCHEMBL5539659 0.90 LSS (0.42) SMN1; SMN2ALDH1A1KDM4EMGLLLMNA
SCHEMBL5546002 0.89 LMNA (0.46) DRD2DRD4SMN1; SMN2ALDH1A1KDM4E
SCHEMBL5546006 0.89 LMNA (0.46) DRD2DRD4SMN1; SMN2ALDH1A1KDM4E
SCHEMBL5539803 0.85 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1VEGFAEGLN1HTT
SCHEMBL5539813 0.85 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1VEGFAEGLN1HTT
SCHEMBL5543012 0.83 MAPT (0.38) SMN1; SMN2ALDH1A1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DRD2 542/4885DRD4 368/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.